1. Home
  2. MTSI vs VTRS Comparison

MTSI vs VTRS Comparison

Compare MTSI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MACOM Technology Solutions Holdings Inc.

MTSI

MACOM Technology Solutions Holdings Inc.

HOLD

Current Price

$282.92

Market Cap

20.1B

Sector

Technology

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$18.14

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTSI
VTRS
Founded
1950
1961
Country
United States
United States
Employees
N/A
30000
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.1B
18.7B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
MTSI
VTRS
Price
$282.92
$18.14
Analyst Decision
Strong Buy
Buy
Analyst Count
10
4
Target Price
★ $257.60
$13.50
AVG Volume (30 Days)
1.2M
★ 7.2M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
★ 3.21%
EPS Growth
★ N/A
N/A
EPS
★ 2.52
0.05
Revenue
$967,258,000.00
★ $14,299,900,000.00
Revenue This Year
$23.55
$4.41
Revenue Next Year
$17.74
$1.96
P/E Ratio
★ $110.54
$365.40
Revenue Growth
★ 32.58
N/A
52 Week Low
$123.86
$9.69
52 Week High
$418.90
$18.39

Technical Indicators

Market Signals
Indicator
MTSI
VTRS
Relative Strength Index (RSI) 54.02 70.17
Support Level $256.10 $15.94
Resistance Level $289.34 $18.23
Average True Range (ATR) 10.98 0.42
MACD 3.06 0.15
Stochastic Oscillator 88.17 87.28

Price Performance

Historical Comparison
MTSI
VTRS

About MTSI MACOM Technology Solutions Holdings Inc.

MACOM Technology Solutions Holdings Inc is a provider of analog, digital, and mixed-signal semiconductor solutions to original equipment manufacturers and distributors. These solutions are found in systems for industrial, medical, scientific, and test and measurement markets. The firm's portfolio of products includes integrated circuits, multichip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: